These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22193945)

  • 1. Nocebo in headaches: implications for clinical practice and trial design.
    Mitsikostas DD
    Curr Neurol Neurosci Rep; 2012 Apr; 12(2):132-7. PubMed ID: 22193945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nocebo in headache.
    Mitsikostas DD
    Curr Opin Neurol; 2016 Jun; 29(3):331-6. PubMed ID: 26926672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches.
    Mitsikostas DD; Mantonakis LI; Chalarakis NG
    Cephalalgia; 2011 Apr; 31(5):550-61. PubMed ID: 21216874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Nocebo Response in Pharmacologic Treatments of Primary Headache: A Systematic Review and Meta-Analysis.
    Zhang Y; Xu Y; Liu S; Liang J; Fan S; Ding M; Wang J; Xiao Z
    J Clin Pharmacol; 2022 Oct; 62(10):1257-1272. PubMed ID: 35532312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice.
    Mitsikostas DD; Chalarakis NG; Mantonakis LI; Delicha EM; Sfikakis PP
    Eur J Neurol; 2012 May; 19(5):672-80. PubMed ID: 21973313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis.
    Jackson JL; Kuriyama A; Kuwatsuka Y; Nickoloff S; Storch D; Jackson W; Zhang ZJ; Hayashino Y
    PLoS One; 2019; 14(3):e0212785. PubMed ID: 30893319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.
    Kokoti L; Drellia K; Papadopoulos D; Mitsikostas DD
    J Neurol; 2020 Apr; 267(4):1158-1170. PubMed ID: 31919565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of placebo-arm dropouts in osteoporosis randomized-controlled trials and implications for nocebo-associated discontinuation of anti-osteoporotic drugs in clinical practice.
    Kravvariti E; Kasdagli MI; Diomatari KM; Mouratidou P; Daskalakis K; Mitsikostas DD; Sfikakis PP; Yavropoulou MP
    Osteoporos Int; 2023 Mar; 34(3):585-598. PubMed ID: 36596944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nocebo and lessebo effects.
    A Mestre T
    Int Rev Neurobiol; 2020; 153():121-146. PubMed ID: 32563285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis.
    Häuser W; Sarzi-Puttini P; Tölle TR; Wolfe F
    Clin Exp Rheumatol; 2012; 30(6 Suppl 74):78-87. PubMed ID: 23137770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study.
    Lipton RB; Stewart WF; Cady R; Hall C; O'Quinn S; Kuhn T; Gutterman D
    Headache; 2000; 40(10):783-91. PubMed ID: 11135021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do we need a new procedure for the assessment of adverse events in anti-migraine clinical trials?
    Amanzio M
    Recent Pat CNS Drug Discov; 2011 Jan; 6(1):41-7. PubMed ID: 21118096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can insights from placebo and nocebo mechanisms studies improve the randomized controlled trial?
    Vase L
    Scand J Pain; 2020 Jul; 20(3):451-467. PubMed ID: 32609651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nocebo in clinical trials for depression: a meta-analysis.
    Mitsikostas DD; Mantonakis L; Chalarakis N
    Psychiatry Res; 2014 Jan; 215(1):82-6. PubMed ID: 24210741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nocebo effect and its relevance for clinical practice.
    Colloca L; Miller FG
    Psychosom Med; 2011 Sep; 73(7):598-603. PubMed ID: 21862825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder. A meta-regression analysis.
    Meister R; Jansen A; Härter M; Nestoriuc Y; Kriston L
    J Affect Disord; 2017 Jun; 215():288-298. PubMed ID: 28363152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes.
    Chavarria V; Vian J; Pereira C; Data-Franco J; Fernandes BS; Berk M; Dodd S
    Clin Ther; 2017 Mar; 39(3):477-486. PubMed ID: 28237673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nocebo effects in multiple sclerosis trials: a meta-analysis.
    Papadopoulos D; Mitsikostas DD
    Mult Scler; 2010 Jul; 16(7):816-28. PubMed ID: 20538704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migraine treatment and placebo effect.
    Speciali JG; Peres M; Bigal ME
    Expert Rev Neurother; 2010 Mar; 10(3):413-9. PubMed ID: 20187863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventative treatment for migraine and tension-type headaches : do drugs having effects on muscle spasm and tone have a role?
    Freitag FG
    CNS Drugs; 2003; 17(6):373-81. PubMed ID: 12696998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.